Lysulin, Inc. Secures Patent for Nutritional Support for People with Diabetes and Prediabetes
Lysulin, Inc. announced today patent approval for their flagship product Lysulin®, a first-in-class nutritional supplement formulated for people with Type 2 diabetes and prediabetes. Lysulin provides a breakthrough approach for blood glucose management in an all-natural product available over the counter, without a prescription.
Lysulin’s approved patents include the prevention of protein glycation using Lysine supplements for a method of monitoring blood sugar control and as a method of treating diabetes using a supplement.
In the pilot double-blind, placebo-controlled clinical study, substantial reductions in Hemoglobin A1c (A1c) test levels were observed in people taking Lysulin as compared to people taking a placebo. Improved insulin resistance and beta cell function were also observed.
Dr. John F. Burd, CEO of Lysulin, Inc., says, “This patent strengthens our company by providing protection from copycat manufacturers. We are very pleased with the performance of Lysulin and we have helped many people with diabetes and prediabetes to better health.”
Dr. Burd was the founder and CEO of DexCom and is renowned for his work in the medical and biotechnology field. He was inducted into the American Association of Clinical Chemistry (AACC) Hall of Fame in 2005 after winning the Ullman prize for innovation in clinical chemistry.
Lysulin’s easy-to-take, chewable tablet is gluten free, vegetarian and vegan. Lysulin is available without a prescription and can be purchased at http://www.lysulin.com.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease.